Innate Pharma

Equities

IPH

FR0010331421

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:10 2024-04-19 am EDT			5-day change	1st Jan Change
2.11 ^EUR	-1.86%		-9.44%	-19.47%

Apr. 15	Sanofi: progress in hematology trial	CF
Apr. 15	Innate Pharma: progress in hematology trial	CF

Innate Pharma : IPH 12.20 Rapport spécial AGE 05 2021 (31 résolution) PEE.pdf

May 07, 2021 at 02:09 am EDT

"#!$% !

!"!#$%&'(

"#!$% !

)%0						$$%&'$
3
	+			.	/		-		"#		"#$$(&)*(	!	+
			+					"#$$(&
,		-		+4		"#**11&)#	+2
				-						.

&(+'!", ( "- ###$( (%')* (

.(('+(((// . (0#

1(( 2,(,//'

-//(/ (,,/'(

/+/*,

// /(0",('

** //

Attachments

Original document
Permalink

Disclaimer

Innate Pharma SA published this content on 07 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2021 06:08:01 UTC.

Latest news about Innate Pharma

Sanofi: progress in hematology trial	Apr. 15	CF
Innate Pharma: progress in hematology trial	Apr. 15	CF
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients	Apr. 15	CI
Innate Pharma: IPH45 data presented at AACR	Apr. 10	CF
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate	Apr. 10	CI
Transcript : Innate Pharma S.A., 2023 Earnings Call, Mar 21, 2024	Mar. 21
Innate Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Innate Pharma initiates lymphoma trial	Mar. 06	CF
Innate Pharma: abstract on IPH45 at the AACR congress	Mar. 06	CF
Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin?s Lymphoma	Mar. 06	CI
Global markets live: Next, Shell, GM, Apple, Nasdaq...	Jan. 04
US FDA Ends Partial Clinical Hold on Innate Pharma's Investigational Cancer Drug	Jan. 04	MT
Innate Pharma Says FDA Lifted Partial Clinical Hold on Lacutamab Clinical Program	Jan. 04	MT
Innate Pharma: FDA suspension lifted	Jan. 04	CF
Innate Pharma appoints two new board members	Jan. 04	CF
Innate Pharma S.A. Announces Executive Changes	Jan. 04	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	Dec. 19	MT
Innate Pharma Shares Rise after Sanofi Exercises Licensing Option	Dec. 19	DJ
Sanofi Exercises Option to License 4th NK Cell Engager Program in Solid Tumors From Innate Pharma's ANKET Platform	Dec. 19	MT
Sanofi Exercises Option to License 4th NK Cell Engager Program in Solid Tumors From Innate Pharma's ANKET Platform	Dec. 19	MT
Sanofi Licenses Natural Killer Cell Engager Program from Innate Pharma	Dec. 19	MT
Innate Pharma: license option exercised by Sanofi	Dec. 19	CF
Innate Pharma S.A. and Sanofi Announce Licensing of Fourth Natural Killer Cell Engager in Oncology to Sanofi	Dec. 19	CI
Innate Pharma: Chairman of the Board resigns	Dec. 18	CF
Innate Pharma Names Herve Brailly as Interim CEO, Chairman	Dec. 18	MT

Chart Innate Pharma

Duration

Period

More charts

Company Profile

Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows: - revenues from collaboration and licensing agreements (84.2%); - government financing for research expenditure (15.8%). At the end of 2023, the company had a portfolio of 7 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas and IPH5201 for the treatment of cancer) and 4 in phase I (IPH5301 for the treatment of solid tumours, IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia, IPH6401 for the treatment of multiple myeloma and IPH6501 for the treatment of non-Hodgkin lymphoma).

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Ratings for Innate Pharma

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.15 EUR

Average target price

6.27 EUR

Spread / Average Target

+191.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INNATE PHARMA	-19.47%	185M
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B

Other Biotechnology & Medical Research